PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.064
EU - Europa 15.280
AS - Asia 13.204
SA - Sud America 1.810
Continente sconosciuto - Info sul continente non disponibili 419
AF - Africa 358
OC - Oceania 75
Totale 57.210
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.436
IT - Italia 5.205
SG - Singapore 3.905
CN - Cina 3.208
GB - Regno Unito 2.543
IE - Irlanda 2.197
HK - Hong Kong 1.502
VN - Vietnam 1.398
BR - Brasile 1.301
DE - Germania 1.181
SE - Svezia 1.025
BD - Bangladesh 799
FR - Francia 569
FI - Finlandia 541
RU - Federazione Russa 484
UA - Ucraina 401
IN - India 400
KR - Corea 365
CA - Canada 344
ID - Indonesia 297
TR - Turchia 289
NL - Olanda 217
BG - Bulgaria 179
AR - Argentina 166
JP - Giappone 147
TW - Taiwan 144
MX - Messico 139
IQ - Iraq 120
ES - Italia 108
PL - Polonia 105
ZA - Sudafrica 81
CO - Colombia 80
LT - Lituania 79
PK - Pakistan 77
CL - Cile 74
AU - Australia 72
BE - Belgio 66
MY - Malesia 66
EC - Ecuador 62
AE - Emirati Arabi Uniti 60
EG - Egitto 59
VE - Venezuela 57
AT - Austria 53
CZ - Repubblica Ceca 45
IR - Iran 43
SA - Arabia Saudita 43
PH - Filippine 42
MA - Marocco 39
JO - Giordania 38
KE - Kenya 34
TH - Thailandia 33
CH - Svizzera 30
NP - Nepal 30
PY - Paraguay 29
RO - Romania 29
UZ - Uzbekistan 28
JM - Giamaica 25
MD - Moldavia 25
CR - Costa Rica 24
AL - Albania 23
IL - Israele 22
TN - Tunisia 22
AZ - Azerbaigian 21
DZ - Algeria 20
GR - Grecia 20
DO - Repubblica Dominicana 19
HU - Ungheria 19
ET - Etiopia 17
EU - Europa 17
HN - Honduras 17
NG - Nigeria 17
PT - Portogallo 17
PE - Perù 16
LB - Libano 15
DK - Danimarca 14
SI - Slovenia 14
SY - Repubblica araba siriana 14
BO - Bolivia 13
MK - Macedonia 13
RS - Serbia 12
LV - Lettonia 11
TT - Trinidad e Tobago 11
BH - Bahrain 10
KZ - Kazakistan 10
OM - Oman 10
UY - Uruguay 10
AO - Angola 9
BY - Bielorussia 9
CI - Costa d'Avorio 9
PA - Panama 9
CY - Cipro 8
MT - Malta 8
PR - Porto Rico 8
QA - Qatar 8
SK - Slovacchia (Repubblica Slovacca) 8
HR - Croazia 7
KG - Kirghizistan 7
SN - Senegal 7
BB - Barbados 6
KH - Cambogia 6
Totale 56.671
Salva come PNG Salva come JPEG
Città #
Ashburn 2.772
Singapore 2.609
Santa Clara 2.534
Dublin 2.189
Fairfield 1.752
San Jose 1.453
Hong Kong 1.445
Chandler 1.433
Southend 1.325
Council Bluffs 1.055
Woodbridge 1.014
Houston 803
Beijing 768
Dearborn 736
Seattle 729
Nyköping 668
Ann Arbor 667
Hefei 644
Wilmington 626
Jacksonville 611
Cambridge 536
Dallas 529
London 523
New York 523
Milan 491
Los Angeles 465
Ho Chi Minh City 441
Helsinki 402
The Dalles 365
Rome 354
Modena 338
Hanoi 312
Seoul 303
Chicago 266
Jakarta 229
Munich 209
Shanghai 205
Lauterbourg 197
Bologna 196
Columbus 183
San Diego 183
Princeton 174
Sofia 169
Moscow 158
Buffalo 148
Eugene 141
Izmir 132
São Paulo 124
Frankfurt am Main 118
Dong Ket 112
Orem 110
Naples 108
Fremont 107
Redwood City 104
Boardman 98
Tokyo 91
Phoenix 86
Salt Lake City 79
Bremen 77
Florence 77
Warsaw 74
Brooklyn 71
Toronto 71
Guangzhou 70
Turin 69
Falls Church 67
Reggio Emilia 65
Bari 62
Atlanta 59
Redondo Beach 57
Genoa 56
Taichung 56
Tampa 56
Chennai 55
Da Nang 55
Parma 54
Montreal 52
Palermo 51
Brussels 50
Mumbai 50
Baghdad 49
Haiphong 49
Amsterdam 46
Norwalk 44
Nuremberg 44
Turku 44
Denver 43
Ottawa 42
Elk Grove Village 41
Mexico City 41
Rio de Janeiro 41
San Francisco 39
Des Moines 38
Johannesburg 38
Verona 38
Santiago 37
Catania 36
Miami 36
Nanjing 36
Paris 36
Totale 37.314
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.175
Oxford Manuale di Medicina Clinica 681
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 640
Abemaciclib: eventi avversi e riduzione di dose. 563
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 499
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 468
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer 464
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 456
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 444
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 435
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 435
GD2 expression in breast cancer. 433
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 432
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 426
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 423
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 420
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 409
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 408
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 403
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 401
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 401
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 395
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 392
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 389
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 388
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 384
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 384
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 380
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 378
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 375
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 374
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 369
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 368
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 368
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 368
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 365
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 364
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 364
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 363
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 359
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 358
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 357
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 356
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 354
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 345
Tumor Stroma Manipulation By MSC 342
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 338
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 337
Achievements and unmet needs in the management of advanced ovarian cancer 335
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 333
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 331
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 330
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 327
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 326
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 325
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 323
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 322
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 322
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 321
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 321
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 320
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 318
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 318
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 317
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 316
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 316
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 316
Immune characterization of breast cancer metastases: prognostic implications. 315
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 314
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 309
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 306
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 304
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 302
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 302
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 301
Breast Location for De Novo Extramedullary Myeloid Sarcoma 299
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 298
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 295
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 293
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 290
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 289
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 288
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 285
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 284
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 284
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 282
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 281
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 279
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 278
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 278
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 277
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 277
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 275
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 273
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 273
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 272
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 271
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 271
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). 270
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 270
Totale 35.952
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.831 0 0 286 129 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20243.725 179 203 239 292 496 314 342 569 150 204 298 439
2024/20259.842 357 209 270 727 1.882 1.501 628 693 967 583 772 1.253
2025/202619.262 1.211 601 1.616 1.833 2.728 1.255 2.462 1.043 1.812 1.947 1.506 1.248
2026/20272.260 681 1.207 372 0 0 0 0 0 0 0 0 0
Totale 57.210